Apothecon Taps Veteran CEO Giri to Spearhead Global Expansion

MUMBAI, India – May 15, 2026 – In a strategic move signaling a new era of aggressive growth, specialty pharmaceutical firm Apothecon Group has appointed industry veteran Shyamakant Giri as its new Group Chief Executive Officer. The appointment, effective May 11, places a leader with over two decades of global pharma experience at the helm of the Everstone Capital-backed company, with a clear mandate to drive strategic expansion in highly regulated markets.

Giri, who will be based in Vadodara, India, is tasked with steering Apothecon through its next growth phase. The company, which comprises India-based Apothecon and US-based Navinta, has built a reputation as a vertically integrated business focused on complex generic drugs and Active Pharmaceutical Ingredients (APIs). This leadership change is a pivotal moment, underscoring a deliberate strategy to leverage seasoned expertise to capitalize on a burgeoning pipeline and expanding market opportunities.

A Proven Leader for a New Era

Shyamakant Giri's resume reads like a blueprint for pharmaceutical leadership. With over 25 years of experience, he brings a deep understanding of both regulated and emerging markets. He joins Apothecon from Gland Pharma Limited, where he served as CEO, overseeing the global operations of the publicly listed injectables giant. His career is marked by significant leadership roles, including a tenure as Managing Director and President for India & Rest of the World Markets at Amneal Pharmaceuticals, where he was instrumental in driving commercial expansion.

His nearly two-decade-long career at Abbott India further solidifies his expertise, where he held senior roles across various divisions. Giri is recognized in the industry for his ability to scale new ventures, execute operational turnarounds, and create value in complex market environments. This experience is precisely what Apothecon's leadership was seeking.

"We are delighted to welcome Shyamakant to the Apothecon Group," said Dr. Mahendra Patel, Co-Founder and Chairman of Apothecon Group, in a statement. "His extensive leadership experience across global pharmaceutical and healthcare businesses makes him well-suited to lead the Company through its next phase of growth. We are excited at the prospect of combining Apothecon's differentiated technical capabilities with his operating and commercial expertise."

The Everstone Capital Playbook

The appointment is not just an internal shuffle but a strategic move orchestrated with the backing of Everstone Capital, the private equity arm of the Singapore-headquartered Everstone Group. The firm, which recently invested approximately $270 million for a substantial stake in Apothecon, has a well-defined playbook for its portfolio companies: install strong leadership to accelerate growth and unlock value.

Everstone's investment thesis in the pharmaceutical sector focuses on high-growth assets with scalable platforms. Their portfolio includes successful ventures like Rubicon Research and Slayback Pharma, demonstrating a pattern of identifying promising pharma businesses and fueling their expansion. For Apothecon, Everstone’s strategy involves accelerating the product pipeline, expanding its commercial footprint into new geographies, and actively pursuing complementary acquisitions.

By bringing in a leader of Giri's caliber, Everstone is making a clear statement about its ambitions for Apothecon. The move aligns with a broader trend of private equity firms investing heavily in Indian pharmaceutical companies that possess specialized capabilities in complex drug development, anticipating significant market opportunities as numerous blockbuster drugs go off-patent in the coming years.

Navigating the Complex Generics Landscape

Apothecon Group operates in the highly competitive and technically demanding world of specialty and complex generics. The group's strength lies in its vertical integration, with R&D and manufacturing facilities in both India (Apothecon) and the United States (Navinta). This dual-shore presence provides a critical advantage in supply chain resilience and access to key global markets.

The company's portfolio is robust, with over 20 approved Abbreviated New Drug Applications (ANDAs) in the US and more than 100 approved dossiers in other markets. Navinta, its US arm, has been particularly successful, securing recent FDA approvals for complex products like Sodium Phenyl Acetate, Carglumic Acid, and Penicillamine. These products often target niche therapeutic areas, including oncology, cardiology, and orphan drugs, which command higher value and face less competition than standard generics.

In his new role, Giri inherits a company with a strong technical foundation and a proven regulatory track record. His challenge will be to build upon this base and accelerate its commercial success.

"I am excited to join Apothecon Group at such an important point in its journey," Giri commented on his appointment. "The Group has built strong capabilities of developing, manufacturing and marketing complex generic drugs with a backward-integrated manufacturing base and differentiated in-house R&D setup. I look forward to partnering with the founders, the Board, and all stakeholders to build on this foundation."

The Road Ahead: Expansion and Innovation

The 'next phase of growth' for Apothecon under Giri's leadership will be multifaceted. A key focus will be leveraging the surging demand in the specialty generics market, which is projected to exceed $120 billion globally in 2026. With patent cliffs looming for many specialty branded drugs, companies like Apothecon are perfectly positioned to capture significant market share.

Giri's experience in commercial expansion will be vital as the company looks to deepen its presence in the United States and Europe while exploring new regulated markets. Furthermore, the financial backing from Everstone provides the war chest needed for strategic, bolt-on acquisitions that can add new technologies, products, or market access.

Internally, the focus will likely be on accelerating the R&D engine to bring more complex formulations and high-potency APIs to market, particularly in high-growth areas like oncology. The company's integrated model is a significant asset, allowing for greater control over quality and supply chains—a factor of increasing importance in a post-pandemic world wary of geopolitical disruptions. With a seasoned navigator at the helm and strong financial winds in its sails, Apothecon Group appears poised to chart an aggressive course into the top tier of the global specialty pharmaceutical industry.